Navigation Links
Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential
Date:2/9/2011

ients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company

Contact: Investor Rel
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Ness County Hospital Selects ChartAccess® Comprehensive EHR from Prognosis Health Information Systems
2. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
3. Cancer Patients in Bangladesh Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems
4. Medicare Patients Report Problems With Access to Medically Required Equipment and Services Under Controversial Competitive Bidding System
5. Access MediQuip Names Prakash Patel Chief Executive Officer
6. Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment
7. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
8. EDC Functionality, Ease of Data Entry, and Access to Data All Factors in University of Virginia Cancer Centers Selection of the OnCore Clinical Research Management System
9. AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device
10. Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants
11. Critical Care Nurses Do Not Have Access to Tools They Need to Treat Sepsis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... and BOSTON , May 24, 2013 /PRNewswire/ ... development company, is pleased to announce that it has engaged Mr ... the Company,s business development capabilities in Japan ... 15 years of experience in business development, licensing and alliance management ... Roche Pharma ( Japan ), Nippon Roche and Tanabe ...
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... May 23, 2013  Haemonetics Corporation (NYSE: HAE ... CFO & EVP-Business Development, will present at The Deutsche Bank ... Boston, MA on May 29, 2013 at ... ) The public may access Mr. Lindop,s presentation ... About Haemonetics Haemonetics (NYSE: HAE ) ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... 21, 2010 /PRNewswire-FirstCall/ – ERT (Nasdaq: ERES ... the pharmaceutical, biotechnology and medical device industries, today confirmed ... of Dr. Michael J. McKelvey, its President and CEO, ... currently ERT,s Chairman and Chief Scientific Officer, has also ...
... 21, 2010 PTC Therapeutics, Inc. announced today that ... trial of ataluren, an investigational new drug, in patients ... http://photos.prnewswire.com/prnh/20010919/PTCLOGO) The 48-week study is designed to ... with nmCF.  The trial has enrolled 238 patients at ...
Cached Medicine Technology:ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO 2ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO 3PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 2PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 3PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 4
(Date:5/24/2013)... 24, 2013 According to the National Institutes ... toxic epidermal necrolysis (TEN) that affects the skin and mucous ... adults under the age of 30 (i). In the ... and fever. As SJS advances, it affects the mucous ... and anus. Inflammation of the eye causes conjunctivitis (pink ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- The number ... units after spending time in an emergency room ... new research. The study, conducted by researchers ... Health and Health Services in Washington, D.C., found ... room on average before being admitted to the ...
(Date:5/24/2013)... new investigational device - the Helio System (TF-FA) - ... Heart Valve was successfully deployed in all four patients ... in high-risk aortic insufficiency reported at EuroPCR 2013. , ... help stabilise the SAPIEN XT valve for patients with ... captured between the transcatheter heart valve and the dock. ...
(Date:5/24/2013)... May 24, 2013 The producers of ... dates for Charlotte, North Carolina. It is one of the ... 500 companies. The city is populated with more than a ... cover residents in both North and South Carolina. Viewers who ... medically-related can tune into WAXN-TV 64 Eyewitness News during the ...
(Date:5/24/2013)... NY (PRWEB) May 24, 2013 The ... is happy to announce that it has donated $10,000 to ... the women held captive in Cleveland, Ohio. , “When the ... Jesus, Michelle Knight, and Amanda Berry and her daughter had ... a decade, we were shocked and horrified,” said Integrative Nutrition ...
Breaking Medicine News(10 mins):Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Feasibility trial reports deployment of new device for TAVI in aortic insufficiency 2Health News:Health Briefs TV Presents May Air Dates for Charlotte, North Carolina 2Health News:Integrative Nutrition Donates $10,000 to the Cleveland Courage Fund 2
... CHAPEL HILL, N.C., May 27 As the ... companies are looking,for ways to up-sell and cross-sell ... the need for such practices, Best Practices LLC ... from less than 5% of their,service calls., ...
... NY/LOS ANGELES, CA: Stand Up To Cancer ... philanthropic dollars for accelerating ground-breaking research, launches today ... networks, entertainment industry executives, celebrities and prominent leaders ... CBS and NBC will donate one hour of ...
... TUCSON, Ariz., May 27 Medipacs, Inc., a ... is has secured an,initial financial investment of $1.65 ... Venture Partners and other investors in Tucson, San,Diego, ... Mark McWilliams comments: "We are very pleased with,the ...
... IMTEC Corporation proudly,introduces a newly redesigned version ... works in conjunction with IMTEC,s proprietary,FlashCT(R) software for ... scanner, Vision provides users with tools for viewing, ... may be in the form of,a raw scan ...
... in Melanoma , Mutations in the p14ARF tumor ... independent of the effect of the p16 gene. , ... on chromosome 9 that is frequently mutated in melanomas. ... p16 tumor suppressor gene occurs frequently in melanomas, it ...
... days off, poor-quality output, study finds , , TUESDAY, May ... hyperactivity disorder (ADHD) miss, on average, more than three ... new global reckoning of the problem. , Altogether, between ... ADHD, according to survey data from the World Health ...
Cached Medicine News:Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 2Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 3Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 4Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 5Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 6Health News:IMTEC Introduces New Vision Software 2Health News:Also in the May 27 JNCI 2Health News:Also in the May 27 JNCI 3Health News:Also in the May 27 JNCI 4Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 2Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 3
The BD Ultra-Fine 33 Lancets are the thinnest lancets available, which means that you'll experience less pain when taking a blood sample....
... blood flow and minimize pain when ... safety-engineered BD Microtainer Quikheel Lancet. The ... blade providing a precise and consistent ... into its casing, helping to protect ...
The HEMOCHRON Signature Elite offers state-of-the-art features like barcode scanning, internal Electronic Quality Control (EQC), QC Lockout and alphanumeric data entry for Patient Identification (PID...
... Our highest throughput solution for ELISA testing. ... 2 Sample Processors, 1 Robot, and 1 ... solution automatically performs: dispensing of samples from ... plate transport via the robotic transport system ...
Medicine Products: